RU2478100C2 - Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы - Google Patents

Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы Download PDF

Info

Publication number
RU2478100C2
RU2478100C2 RU2010116759/04A RU2010116759A RU2478100C2 RU 2478100 C2 RU2478100 C2 RU 2478100C2 RU 2010116759/04 A RU2010116759/04 A RU 2010116759/04A RU 2010116759 A RU2010116759 A RU 2010116759A RU 2478100 C2 RU2478100 C2 RU 2478100C2
Authority
RU
Russia
Prior art keywords
cyclopentyl
pyrimido
oxo
ylamino
methyl
Prior art date
Application number
RU2010116759/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010116759A (ru
Inventor
Джонатан Джеймс ХОЛЛИК
Стюарт Дональд ДЖОУНС
Клер Джун ФЛИНН
Майкл Джордж ТОМАС
Original Assignee
Сайкласел Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0719038A external-priority patent/GB0719038D0/en
Priority claimed from GB0806844A external-priority patent/GB0806844D0/en
Application filed by Сайкласел Лимитед filed Critical Сайкласел Лимитед
Publication of RU2010116759A publication Critical patent/RU2010116759A/ru
Application granted granted Critical
Publication of RU2478100C2 publication Critical patent/RU2478100C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2010116759/04A 2007-09-28 2008-09-29 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы RU2478100C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0719038.2 2007-09-28
GB0719038A GB0719038D0 (en) 2007-09-28 2007-09-28 Compound
GB0806844.7 2008-04-15
GB0806844A GB0806844D0 (en) 2008-04-15 2008-04-15 Compound
PCT/GB2008/003305 WO2009040556A1 (en) 2007-09-28 2008-09-29 Pyrimidine derivatives as protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2013108456A Division RU2623221C2 (ru) 2007-09-28 2013-02-26 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы

Publications (2)

Publication Number Publication Date
RU2010116759A RU2010116759A (ru) 2011-11-10
RU2478100C2 true RU2478100C2 (ru) 2013-03-27

Family

ID=40199600

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010116759/04A RU2478100C2 (ru) 2007-09-28 2008-09-29 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы
RU2013108456A RU2623221C2 (ru) 2007-09-28 2013-02-26 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013108456A RU2623221C2 (ru) 2007-09-28 2013-02-26 Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы

Country Status (9)

Country Link
US (3) US8563542B2 (OSRAM)
EP (2) EP2205603B1 (OSRAM)
JP (2) JP5410432B2 (OSRAM)
CN (1) CN101878216B (OSRAM)
CA (1) CA2700979C (OSRAM)
ES (2) ES2585110T3 (OSRAM)
PL (2) PL2610256T3 (OSRAM)
RU (2) RU2478100C2 (OSRAM)
WO (1) WO2009040556A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748696C2 (ru) * 2016-03-04 2021-05-28 Аньхой Нью Стар Фармасьютикал Дивелопмент Ко., Лтд Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007008837D1 (de) 2006-02-14 2010-10-14 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
MX2010003249A (es) 2007-09-25 2010-11-09 Takeda Pharmaceutical Inhibidores de quinasas símil polo.
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
CN102076691A (zh) 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
KR20110039278A (ko) 2008-06-23 2011-04-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
NZ599356A (en) 2009-09-25 2013-08-30 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
KR20120096474A (ko) 2009-09-25 2012-08-30 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
MX2012014158A (es) 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
ES2653967T3 (es) 2010-11-10 2018-02-09 Genentech, Inc. Derivados de pirazol aminopirimidina como moduladores de LRRK2
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
US9676792B2 (en) * 2013-03-15 2017-06-13 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
EP3068782B1 (en) 2013-11-13 2018-05-23 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
KR101517414B1 (ko) * 2014-04-24 2015-05-04 고려대학교 산학협력단 염증성 질환의 예방 또는 치료용 약학 조성물
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
CN107148424B (zh) 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
CN109311901A (zh) * 2016-04-07 2019-02-05 达纳-法伯癌症研究所有限公司 嘧啶并-二氮杂卓酮激酶骨架化合物及治疗pi3k介导的病变的方法
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
US20200347033A1 (en) * 2017-11-02 2020-11-05 Calico Life Sciences Llc Modulators of the integrated stress pathway
EP4013502B8 (en) 2019-08-16 2025-10-22 Cyclacel Pharmaceuticals, Inc. Process for the preparation of a pyrimidino-diazepine derivative
JP7736311B2 (ja) 2019-08-16 2025-09-09 サイクラセル リミテッド ピリミジノジアゼピン誘導体の結晶性形態
AU2020356484A1 (en) * 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
WO2023196943A1 (en) 2022-04-08 2023-10-12 Inhibrx, Inc. Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100194A1 (en) * 2004-10-04 2006-05-11 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2007095188A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
EA008778B1 (ru) * 2003-02-26 2007-08-31 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117635D0 (en) 1991-08-15 1991-10-02 British Telecomm Phase shifter
GB0302220D0 (en) 2003-01-30 2003-03-05 Cyclacel Ltd Use
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2005117944A2 (en) 2004-05-26 2005-12-15 The Texas A & M University System Hsp20 inhibits amyloidogenesis and neurotoxicity
BRPI0611705A2 (pt) 2005-06-24 2016-11-16 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
JP5087640B2 (ja) * 2007-03-22 2012-12-05 武田薬品工業株式会社 Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン
MX2010003249A (es) * 2007-09-25 2010-11-09 Takeda Pharmaceutical Inhibidores de quinasas símil polo.
CN101878216B (zh) * 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2010083505A1 (en) 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
GB201205752D0 (en) 2012-03-30 2012-05-16 Cyclacel Ltd Treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008778B1 (ru) * 2003-02-26 2007-08-31 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
US20060100194A1 (en) * 2004-10-04 2006-05-11 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2007095188A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748696C2 (ru) * 2016-03-04 2021-05-28 Аньхой Нью Стар Фармасьютикал Дивелопмент Ко., Лтд Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение

Also Published As

Publication number Publication date
CA2700979C (en) 2017-06-20
RU2010116759A (ru) 2011-11-10
US20140066436A1 (en) 2014-03-06
EP2205603A1 (en) 2010-07-14
JP5410432B2 (ja) 2014-02-05
HK1187895A1 (en) 2014-04-17
JP5863196B2 (ja) 2016-02-16
WO2009040556A1 (en) 2009-04-02
CN101878216A (zh) 2010-11-03
CA2700979A1 (en) 2009-04-02
US20110046093A1 (en) 2011-02-24
ES2585110T3 (es) 2016-10-03
EP2205603B1 (en) 2014-01-15
RU2623221C2 (ru) 2017-06-23
EP2610256A1 (en) 2013-07-03
JP2014076994A (ja) 2014-05-01
US20150344486A1 (en) 2015-12-03
PL2610256T3 (pl) 2016-11-30
ES2457394T3 (es) 2014-04-25
JP2010540509A (ja) 2010-12-24
CN101878216B (zh) 2013-07-10
PL2205603T3 (pl) 2014-07-31
EP2610256B1 (en) 2016-04-27
RU2013108456A (ru) 2014-09-10
US9133199B2 (en) 2015-09-15
US8563542B2 (en) 2013-10-22
US9493471B2 (en) 2016-11-15
HK1146042A1 (en) 2011-05-13

Similar Documents

Publication Publication Date Title
RU2478100C2 (ru) Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы
AU2011217961B2 (en) Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors
JP3876254B2 (ja) 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用
US8592581B2 (en) Trisubstituted purine derivatives
EP1786779B1 (en) 4-arylazo-3,5-diamino-pyrazole compounds and use thereof
US9233965B2 (en) 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta
JP2007504159A (ja) プロテインキナーゼ阻害剤としての化合物および組成物
EP1589967B1 (en) Benzthiazole-3 oxides useful for the treatment of proliferative disorders
JP2005519087A (ja) １−［アルキル］、１−［（ヘテロアリール）アルキル］および１−［（アリール）アルキル］−７−（ピリミジン−４−イル）−イミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体
US20110118269A1 (en) Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
US20230312576A1 (en) 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
HK1146042B (en) Pyrimidine derivatives as protein kinase inhibitors
HK1187895B (en) Pyrimidine derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PD4A Correction of name of patent owner